Skip to main content

Canine IL-17 Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB5848

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
MAB5848
MAB5848-SP

Key Product Details

Species Reactivity

Canine

Applications

Neutralization

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2A Clone # 665909

Product Specifications

Immunogen

E. coli-derived recombinant canine IL-17
Gly26-Ala155
Accession # NP_001159350

Specificity

Detects canine IL-17 in direct ELISAs. In direct ELISAs, approximately 25% cross-reactivity with recombinant human (rh) IL-17A is observed and no cross-reactivity with rhIL-17F or recombinant mouse IL-17A is observed.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2A

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Canine IL-17 Antibody

IL-6 Secretion Induced by IL‑17 and Neutralization by Canine IL‑17 Antibody.

IL-6 Secretion Induced by IL‑17 and Neutralization by Canine IL‑17 Antibody.

Recombinant Canine IL-17 (Catalog # 5848-CL) induces IL-6 secretion in the NIH-3T3 mouse embryonic fibroblast cell line in a dose-dependent manner (orange line). IL-6 Secretion elicited by Recombinant Canine IL-17 (5 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Canine IL-17 Monoclonal Antibody (Catalog # MAB5848). The ND50 is typically 5-30 ng/mL.

Applications for Canine IL-17 Antibody

Application
Recommended Usage

Neutralization

Measured by its ability to neutralize IL‑17-induced IL-6 secretion in the NIH‑3T3 mouse embryonic fibroblast cell line. Yao, Z. et al. (1995) Immunity 3:811.The Neutralization Dose (ND50) is typically 5-30 ng/mL in the presence of 5 ng/mL Recombinant Canine IL‑17.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Sterile PBS to a final concentration of 0.5 mg/mL. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-17/IL-17A

Interleukin 17 (IL-17; also IL-17A and CTLA-8) is a 17 kDa member of the IL-17 family of cytokines (1). Members of this family demonstrate a structural motif termed a cysteine knot which characterize a large superfamily of growth factors. Although most cysteine knot superfamily members use three intrachain disulfide bonds to create a knot, IL-17 family molecules generate the same structural form with only two disulfide links (2-4). Based on the amino acid (aa) sequence alignment with human IL-17, canine IL-17 is 130 aa in length. It is secreted as a 35 kDa disulfide-linked homodimer and as a 40 kDa disulfide-linked heterodimer with IL-17F (5). Canine IL‑17 is 81% identical on the aa level to human IL-17. IL-23 drives Th17 lymphocytes to produce IL-17 (6-8). IL-17’s production has also been demonstrated in gamma delta T cells (9), CD8+ memory T cells (10-11), eosinophils (12), neutrophils (10), and monocytes (13). Studies have identified that the widely expressed receptors IL‑17RA and IL-17RC form a heterodimer for the binding of IL-17 (6, 14-15).  The predominant function of IL-17 is thought to be as a proinflammatory mediator through a variety of mechanisms (16). Locally, IL‑17 stimulates production of IL-6, prostaglandin E and nitric oxide (16-19), and synergy with other inflammatory cytokines such as TNF-alpha, IL‑1 beta and IFN -gamma leads to up-regulation of gene expression and progression and amplification of local inflammation (16, 20-22). IL‑17 also mediates chemotaxis of neutrophils and monocytes to sites of inflammation through the chemoattractant mediators IL-8, GRO‑ alpha, and MCP-1 (16, 22-25) while augmenting production of hematopoietic growth factors, such as G-CSF and GM-CSF (16, 26, 27), which promote the growth and maturation of the recruited myeloid cells. In addition, IL-17 serves as a bridge between innate and adaptive immune responses by enhancing the induction of co-stimulatory molecules such as ICAM-1 and other cytokines (16, 22, 28), thereby supporting T cell activation. IL-17 expression has been associated with many inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, asthma, systemic lupus erythematosus and allograft rejection (15).

References

  1. Gaffen, S.L. et al. (2006) Vitam. Horm. 74:255.
  2. Kawaguchi, M. et al. (2004) J. Allergy Clin. Immunol. 114:1265.
  3. Kolls, J.K. and A. Linden (2004) Immunity 21:467.
  4. Moseley, T.A. et al. (2003) Cytokine Growth Factor Rev. 14:155.
  5. Wright, J.F. et al. (2007) J. Biol. Chem. 282:13447.
  6. Cheung, P.F.Y. et al. (2008) J. Immunol. 180:5625.
  7. Steinman, L. (2007) Nat. Med. 13:139.
  8. Hunter, C.A. (2005) Nat. Rev. Immunol. 5:521.
  9. Lockhart, E. et al. (2006) J. Immunol. 177:4662.
  10. Ferretti, S. et al. (2003) J. Immunol. 170:2106.
  11. Shin, H.C. et al. (1999) Cytokine 11:257.
  12. Molet, S. et al. (2001) J. Allergy Clin. Immunol. 108:430.
  13. Zhou, Q. et al. (2005) Infect. Immun. 73:935.
  14. Kuestner, R.E. et al. (2007) J. Immunol. 179:5462.
  15. Chang, S.H. and C. Dong (2007) Cell Res. 17:435.
  16. Afzali, B. et al. (2007) Clin. Exp. Immunol. 148:32.
  17. Fossiez, F. et al. (1996) J. Exp. Med. 183:2593.
  18. Yao, Z. et al. (1995) Immunity 3:811.
  19. Attur, M.G. et al. (1997) Arthritis Rheum. 40:1050.
  20. Ruddy, M.J. et al. (2004) J. Biol. Chem. 279:2559.
  21. Albanesi, C. et al. (1999) J. Immunol. 162:494.
  22. Witowski, J. et al. (2000) J. Immunol. 165:5814.
  23. Miyamoto, M. et al. (2003) J. Immunol. 170:4665.
  24. Ye, P. et al. (2001) Am. J. Respir. Cell Mol. Biol. 25:335.
  25. Laan, M. et al. (2001) Br. J. Pharmacol. 133:200.
  26. Starnes, T. et al. (2002) J. Immunol. 169:642.
  27. Jones, C.E. et al. (2002) Am. J. Respir. Cell Mol. Biol. 26:748.
  28. Yao, Z. et al. (1995) J. Immunol. 155:5483.

Long Name

Interleukin 17

Alternate Names

CTLA-8, CTLA8, IL-17A, IL17, IL17A

Entrez Gene IDs

3605 (Human); 16171 (Mouse); 301289 (Rat); 449530 (Porcine); 481837 (Canine); 102119976 (Cynomolgus Monkey)

Gene Symbol

IL17A

UniProt

Additional IL-17/IL-17A Products

Product Documents for Canine IL-17 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Canine IL-17 Antibody

For research use only

Loading...
Loading...
Loading...
Loading...